Combination therapy for advanced pancreatic cancer using Herceptin™ plus chemotherapy

被引:0
作者
Büchler, P
Reber, HA
Eibl, G
Roth, MA
Büchler, MW
Friess, H
Isacoff, WH
Hines, OJ
机构
[1] Heidelberg Univ, Dept Gen Surg, D-69120 Heidelberg, Germany
[2] Univ Calif Los Angeles, Dept Surg, UCLA Sch Med, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, Dept Med, UCLA Sch Med, Los Angeles, CA 90024 USA
关键词
pancreatic cancer; Herceptin; orthotopic animal; model; gemcitabine; docetaxel;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The HER2/neu oncogene is overexpressed in up to 70% of human pancreatic cancer specimens when compared to normal pancreatic tissue. This cell surface receptor can be targeted specifically by the neutralizing antibody Herceptin(TM). Herceptin has been Successfully used in combination with other chemotherapeutic agents in breast cancer, a cancer in which only 30% of patients harbor elevated HER2/neu levels. In the present study, we investigated the therapeutic efficacy of Herceptin in combination with gemcitabine and docetaxel. Gemcitabine is currently the standard chemotherapeutic agent used to treat pancreatic cancer. In contrast, docetaxel, a taxane, is only just being investigated in pancreatic cancer. Tumor cell resistance to taxanes is at least in part mediated by the HER2/NEU oncogene. We have previously characterized IIER2/NEU expression in human pancreatic cancer cell lines and studied the anti-tumor activity of Herceptin monotherapy in vitro and in vivo. In the present study, combination therapy resulted in a dramatic improvement of animals bearing human pancreatic cancer xenografts. Furthermore, metastasis and production of ascites was lower when a combination of these three agents was used. We conclude that, as with breast cancer, the anti-tumor activity of Herceptin may be improved by combination with taxanes or gemcitabine.
引用
收藏
页码:1125 / 1130
页数:6
相关论文
共 50 条
[41]   Effects of Alkalization Therapy on Chemotherapy Outcomes in Advanced Pancreatic Cancer: A Retrospective Case-Control Study [J].
Hamaguchi, Reo ;
Ito, Takashi ;
Narui, Ryoko ;
Morikawa, Hiromasa ;
Uemoto, Shinji ;
Wada, Hiromi .
IN VIVO, 2020, 34 (05) :2623-2629
[42]   Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer [J].
Magnino, A ;
Gatti, M ;
Massucco, P ;
Sperti, E ;
Faggiuolo, R ;
Regge, D ;
Capussotti, L ;
Gabriele, P ;
Aglietta, M .
ONCOLOGY, 2005, 68 (4-6) :493-499
[43]   Chemotherapy in patients with advanced pancreatic cancer: too close to death? [J].
Frigeri, M. ;
De Dosso, S. ;
Castillo-Fernandez, O. ;
Feuerlein, K. ;
Neuenschwander, H. ;
Saletti, P. .
SUPPORTIVE CARE IN CANCER, 2013, 21 (01) :157-163
[44]   Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial [J].
Jeremy L Davis ;
Prakash Pandalai ;
R Taylor Ripley ;
Russell C Langan ;
Seth M Steinberg ;
Melissa Walker ;
Mary Ann Toomey ;
Elliot Levy ;
Itzhak Avital .
Trials, 12
[45]   Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer [J].
Sohn, Byeong Seok ;
Yuh, Young Jin ;
Song, Hong Suk ;
Kim, Bong-Seog ;
Lee, Kyung Hee ;
Jang, Joung-Soon ;
Kim, Sung Rok .
ONCOLOGY LETTERS, 2015, 10 (02) :1204-1210
[46]   Developing effective combination therapy for pancreatic cancer: An overview [J].
Miller, Aubrey L. ;
Garcia, Patrick L. ;
Yoon, Karina J. .
PHARMACOLOGICAL RESEARCH, 2020, 155
[47]   Survival Benefit with the Combination of Docetaxel, Gemcitabine and Erlotinib in Advanced and/or Metastatic Pancreatic Cancer Patients [J].
Samelis, Georgios F. ;
Ekmektzoglou, Konstantinos ;
Tsiakou, Andriani ;
Giannakaki, Styliani ;
Konstadoulakis, Manoussos .
HEPATO-GASTROENTEROLOGY, 2011, 58 (110) :1776-1781
[48]   Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study [J].
Xenidis, N. ;
Chelis, L. ;
Amarantidis, K. ;
Chamalidou, E. ;
Dimopoulos, P. ;
Courcoutsakis, N. ;
Tentes, A. ;
Chiotis, A. ;
Prassopoulos, P. ;
Kakolyris, S. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) :477-484
[49]   Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study [J].
N. Xenidis ;
L. Chelis ;
K. Amarantidis ;
E. Chamalidou ;
P. Dimopoulos ;
N. Courcoutsakis ;
A. Tentes ;
A. Chiotis ;
P. Prassopoulos ;
S. Kakolyris .
Cancer Chemotherapy and Pharmacology, 2012, 69 :477-484
[50]   Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy [J].
Arya, Geetanjali ;
Vandana, Mallaredy ;
Acharya, Sarbari ;
Sahoo, Sanjeeb K. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (06) :859-870